Partnerships & Collaborations
ImmuPharma works actively with partners and collaborators within both industry and academia to support its business strategy and to achieve the Company’s goals.
ImmuPharma and US Avion Pharmaceuticals signed exclusive license and development agreement for LupuzorTM to initially fund a new ‘optimised’
international Phase 3 trial. Following guidance from the FDA post the PK Study completed in H1 2022, Avion and ImmuPharma have agreed to commence a dose ranging Phase 2/3 adaptive study. See announcement
- LupuzorTM study funded up to $25m
- Milestones up to $70m & tiered double-digit royalties up to 17%
- Avion Pharmaceuticals has the exclusive rights for the commercialisation of LupuzorTM in the US
- ImmuPharma retains all the rights to commercialise LupuzorTM
outside of the US
Avion Pharmaceuticals also has the right to explore clinical development for other auto-immune indications within US territories.
Professor Sylviane Muller
Inventor of Lupuzor™ and P140 technology
Professor Muller earned her doctorate in sciences at the University of Strasbourg (France) and focused on immune responses as a postdoctoral researcher at the Max Planck Institute for Immunobiology in Freiburg (Germany). She is Professor at the Institute of Advanced Studies of the Strasbourg University where she holds the chair in Therapeutic immunology; emeritus Research Director at the Centre National de la Recherche Scientifique; former Director of the CNRS Unit Immunopathology and therapeutic chemistry (2001-2017) and…Read more..
Director of the CNRS Institute of Molecular and Cellular Biology (2016-2017). She was the former Director of the Drug Discovery Center for cancer and inflammation Medalis awarded ‘Laboratory of Excellence’ (2011-2020) and now, of the Strasbourg Institute for drug development and discovery (2021-2028; 250 persons). She received several national and international awards (CNRS Silver Medal, CNRS Innovation Award, Léon Velluz Prize from the French Academy of Sciences, finalist of the 2017 European Inventor Award). She is a fellow of the European Academy of Sciences and Member of the Academia Europaea. Her expertise in peptide immunochemistry, combined with insights into the molecular and cellular pathways behind autoimmune diseases, led to the discovery of Lupuzor™, a therapeutic peptide currently evaluated in phase III-clinical trials for Lupus. Using synthetic peptides as tools, she published numerous papers describing the fine characterisation of autoantibodies and autoreactive T lymphocytes, especially in human lupus, and the design of innovative vaccines. Professor Muller has filed over 30 patents and published 395 papers and reviews in peer-reviewed journals.
Your long text In September 2021, Professor Muller was awarded the highly prestigious Legion d’honneur Award.
Europe’s largest fundamental research institution and ImmuPharma’s long standing collaboration partner.
ImmuPharma’s low risk-strategy is to capitalise on pioneering research taking place primarily at Europe’s largest fundamental research institution, the Centre National de la Recherche Scientifique (National Center for Scientific Research) or CNRS. The CNRS was founded in 1939 and is a government-funded research organisation, under the administrative authority of France’s Ministry of Research and has over…Read more..
30,000 employees and an annual budget of over €3 billion. The CNRS has received many prestigious awards and has produced 17 Nobel laureates and 11 Fields Medal award winners.
We have a significant collaborative research and development agreement with the CNRS, which grants ImmuPharma worldwide exclusive rights to exploit commercially certain discoveries.
Our link with the CNRS allows ImmuPharma access to many scientists and doctors, keeping our costs low by avoiding the constant funding necessary for early stage research.
Alongside our collaborations, we are using innovative technologies to develop a strong proprietary discovery pipeline and patented portfolio of potential new lead compounds.
Given the exciting new P140 platform of opportunities created by Professor Muller’s work, we are establishing a new broad agreement with the CNRS, in order to support this important research, provide therapies for other conditions, outside of Lupus and CIDP and to maximise commercial opportunities.